SG
GDTC icon

StoneX Group’s CytoMed Therapeutics GDTC Stock Holding History

StoneX Group’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,356
Closed -$13.8K – 1048
2025
Q4 		$13.8K Buy
+10,356
New +$20.1K ﹤0.01% 988

Other funds holding GDTC

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

StoneX Group's GDTC Position: Q1 2026 in Review

StoneX Group sold out of CytoMed Therapeutics (GDTC) in Q1 2026, closing a stake of 10,356 shares — an estimated $13.8K sold.

StoneX Group first reported a position in GDTC in Q4 2025 and held it in 1 quarter. The position peaked at $13.8K in Q4 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q1 2026.

  • StoneX Group reported no remaining CytoMed Therapeutics position as of Q1 2026 after selling out during the quarter.
  • StoneX Group sold 10,356 CytoMed Therapeutics shares in Q1 2026, an estimated $13.8K.
  • StoneX Group first reported a position in CytoMed Therapeutics in Q4 2025 and held it in 1 quarter.
  • StoneX Group's CytoMed Therapeutics position peaked at $13.8K in Q4 2025.
  • 3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.